This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cong, M.-e.
Right arrow Articles by García-Lerma, J. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cong, M.-e.
Right arrow Articles by García-Lerma, J. G.

 Previous Article  |  Next Article 

Journal of Virology, March 2007, p. 3037-3041, Vol. 81, No. 6
0022-538X/07/$08.00+0     doi:10.1128/JVI.02712-06

The Fitness Cost of Mutations Associated with Human Immunodeficiency Virus Type 1 Drug Resistance Is Modulated by Mutational Interactions{triangledown}

Mian-er Cong, Walid Heneine, and J. Gerardo García-Lerma*

Division of HIV/AIDS Prevention, National Center for HIV, Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, Georgia 30333

Received 8 December 2006/ Accepted 19 December 2006

It is generally accepted that the fitness cost of resistance mutations plays a role in the persistence of transmitted drug-resistant human immunodeficiency virus type 1 and that mutations that confer a high fitness cost are less able to persist in the absence of drug pressure. Here, we show that the fitness cost of reverse transcriptase (RT) mutations can vary within a 72-fold range. We also demonstrate that the fitness cost of M184V and K70R can be decreased or enhanced by other resistance mutations such as D67N and K219Q. We conclude that the persistence of transmitted RT mutants might range widely on the basis of fitness and that the modulation of fitness cost by mutational interactions will be a critical determinant of persistence.

* Corresponding author. Mailing address: Centers for Disease Control and Prevention, 1600 Clifton Road NE, Bldg. 18, MS G-45, Atlanta, GA 30333. Phone: (404) 639-4987. Fax: (404) 639-1174. E-mail: GGarcia-lerma{at}cdc.gov.

{triangledown} Published ahead of print on 27 December 2006.

Journal of Virology, March 2007, p. 3037-3041, Vol. 81, No. 6
0022-538X/07/$08.00+0     doi:10.1128/JVI.02712-06




This article has been cited by other articles:

  • Puertas, M. C., Buzon, M. J., Artese, A., Alcaro, S., Menendez-Arias, L., Perno, C. F., Clotet, B., Ceccherini-Silberstein, F., Martinez-Picado, J. (2009). Effect of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Polymorphism Leu-214 on Replication Capacity and Drug Susceptibility. J. Virol. 83: 7434-7439 [Abstract] [Full Text]  
  • Hue, S., Gifford, R. J., Dunn, D., Fernhill, E., Pillay, D., on Behalf of the UK Collaborative Group on HIV Dru, (2009). Demonstration of Sustained Drug-Resistant Human Immunodeficiency Virus Type 1 Lineages Circulating among Treatment-Naive Individuals. J. Virol. 83: 2645-2654 [Abstract] [Full Text]  
  • Paredes, R., Sagar, M., Marconi, V. C., Hoh, R., Martin, J. N., Parkin, N. T., Petropoulos, C. J., Deeks, S. G., Kuritzkes, D. R. (2009). In Vivo Fitness Cost of the M184V Mutation in Multidrug-Resistant Human Immunodeficiency Virus Type 1 in the Absence of Lamivudine. J. Virol. 83: 2038-2043 [Abstract] [Full Text]  
  • Coutsinos, D., Invernizzi, C. F., Xu, H., Moisi, D., Oliveira, M., Brenner, B. G., Wainberg, M. A. (2009). Template Usage Is Responsible for the Preferential Acquisition of the K65R Reverse Transcriptase Mutation in Subtype C Variants of Human Immunodeficiency Virus Type 1. J. Virol. 83: 2029-2033 [Abstract] [Full Text]  
  • Little, S. J., Frost, S. D. W., Wong, J. K., Smith, D. M., Pond, S. L. K., Ignacio, C. C., Parkin, N. T., Petropoulos, C. J., Richman, D. D. (2008). Persistence of Transmitted Drug Resistance among Subjects with Primary Human Immunodeficiency Virus Infection. J. Virol. 82: 5510-5518 [Abstract] [Full Text]  
  • Kelly, R. M., Leemhuis, H., Gatjen, L., Dijkhuizen, L. (2008). Evolution toward Small Molecule Inhibitor Resistance Affects Native Enzyme Function and Stability, Generating Acarbose-insensitive Cyclodextrin Glucanotransferase Variants. J. Biol. Chem. 283: 10727-10734 [Abstract] [Full Text]  
  • Dykes, C., Demeter, L. M. (2007). Clinical Significance of Human Immunodeficiency Virus Type 1 Replication Fitness. Clin. Microbiol. Rev. 20: 550-578 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»